Findings
========

Background
----------

Infection with human immunodeficiency virus type 1 (HIV-1) is characterised by a gradual and progressive CD4+ T-helper cell depletion \[[@B1]\]. The Fas mediated mechanism of apoptosis during activation induced cell death (AICD) system is a key regulator of apoptosis in normal and malignant T cells \[[@B2],[@B3]\]. Many studies have shown that the mechanism of T-cell receptor(TCR)-triggered activated induce cell death (AICD) in peripheral T-cell mediated via CD95 receptor/ligand interaction are up regulated and involved in this loss of CD4+ cells in HIV-1 infected patients\[[@B2],[@B4]\]. All T-lymphocytes cells express the CD95 cell-surface receptor, a member of the TNF-R/NGT-R super family, which can induce apoptosis upon oligomerization with its ligand, resulting to CD4+ T-cell death \[[@B5]\].

In spite of these, the exact mechanisms by which these cell depletions occur are not clearly understood. Secondly it is not known if these mechanisms are universally similar irrespective of study population or viral type.

In this study we evaluated the plasma concentration of soluble Fas receptors and ligands in HIV-positive patients and compared them to HIV-negative controls. We also assessed the relationship between plasma concentrations of each of Fas receptors and ligands with CD4+ lymphocyte cell counts in HIV-1 positive patients in Cameroon, a population with a known diversity of HIV-1 in which these pathways have not been previously assessed.

Methods
=======

This study was reviewed and approved by Faculty of Medicine and Biomedical Sciences in Yaoundé, Cameroon.

Thirty-nine antiretroviral naïve HIV-1 positive and negative participants were recruited from the Centre for the Study and Control of Communicable Diseases (CSCCD) of the Faculty of Medicine and Biomedical Sciences in Yaoundé, Cameroon. After obtaining written consent, demographic data were recorded from each participant using a standardized questionnaire. Ten ml of blood was collected in EDTA anticoagulant tubes from each participant. The blood was then centrifuged at 12000rpm for five minutes and plasma separated and stored in two vials of 1.5ml each. The plasma was then analyzed for Fas receptor (CD95) and Fas ligands (CD95L) in both HIV-1 positive and negative samples using two different quantitative sandwich ELISA kits (Quantikine®, R&D Systems , UK). All samples were analysed based on the manufacturers' guidelines. It is worth noting that this assays will detect any Fas ligands (or receptors) present in plasma and thus the sensitivity is not expected to be reduced because of the presence of receptor-ligand complexes.

Data were entered into a Microsoft Excel spreadsheet and analysed using STATA version 8 (STATA Corps Texas USA). Plasma levels of Fas receptor and Fas ligands levels in HIV positive and negative participants were compared using the Mann-Whitney U-Test. A spearman rank correlation coefficient was used to determine the correlation between each of Fas receptors and Fas ligands with CD4+ cell counts. These data are available, upon request, from the corresponding author.

Results
=======

Of the 39 participants , 19 (49%) were females and 27 (69%) were HIV-1 seropositive. Plasma levels of Fas receptors were higher in HIV-1 positive subjects with (median = 1486pg/ml, IQR = 1193, 1830pg/ml) compared to HIV-1 negative subjects (median = 1244pg/ml, IQR = 1109, 1325pg/ml) with a p-value of 0.005 (Figure [1](#F1){ref-type="fig"}). The levels of ligands in HIV-positive subjects (median = 154pg/ml, IQR = 111, 203pg/ml) were also higher compared to that in HIV-negative subjects (median = 51pg/ml, IQR = 32, 88pg/ml) with a p-value = 0.001(Figure [1](#F1){ref-type="fig"}).

![**Plasma concentration of Fas receptors (top panel) and Fas ligands (bottom panel) by HIV-1 status in 39 participants in Yaounde, Cameroon.** The middle horizontal lines represent the median concentrations of Fas ligands or Fas receptors.](1756-0500-5-322-1){#F1}

There was a weak correlation between plasma concentrations of Fas receptors and Fas ligands with a Spearman correlation coefficient of 0.32.(Figure [2](#F2){ref-type="fig"}).

![**Correlation between plasma levels of Fas receptors and Fas ligands in 39 participants in Yaounde, Cameroon.** The dots are the individual observations and the straight line is the line of best fit.](1756-0500-5-322-2){#F2}

Plasma concentrations of soluble Fas receptors and ligands were negatively (though not statistically significantly) correlated with the CD4+ cell counts of HIV-positive patients: the correlation coefficients were -0.34 (p-value = 0.78) and -0.3 (p-value = 0.51) respectively (Figure [3](#F3){ref-type="fig"}).

![**Correlation between CD4+ cell counts and plasma levels of each of Fas receptors (upper panel) and Fas ligands (lower panel) in 27 HIV-positive participants in Yaounde, Cameroon.** For each panel, the dots are the individual observations and the straight line is the line of best fit.](1756-0500-5-322-3){#F3}

Discussion
==========

This study aimed at evaluating the plasma concentrations of soluble Fas receptors and ligands in relation to CD4+ cell depletion in a population with high HIV-1 genetic diversity. Our results show an increase in the levels of Fas receptors and ligands in HIV-1 positive patients compared to HIV-negative subjects. Some previous studies described an increase in Fas receptor expression in T-cells from HIV-1 infected children and adults \[[@B3]-[@B7]\]. In a similar study it was also shown that the membrane-bound Fas levels were higher in lymphocytes of HIV-1 positive compared to HIV-negative patients; an increase explained as resulting from a reduction in the pressure mounted on the normal immune system of HIV-uninfected cells when compared to infected cells \[[@B8]-[@B11]\]. The increase in Fas receptors and ligands in HIV-1 infected patients could be in concordance with Fas ligand shedding during T-cell activations, as most T-cells are under pressure from the virus \[[@B4]\].

We also found a depletion of the levels of CD4+ with increased Fas ligands and Fas receptors though this was not statistically significant.

While this study is strengthened by the inclusion of samples from Cameroon, with high HIV diversity, some limitations need to be considered. The relatively small sample size may have lowered the power to identify significant correlations between the Fas Ligands and CD4 counts. We did not analyze the correlation with viral load and HIV subtype. The cross-sectional nature of the study did not allow for establishing whether the time relationship between Fas ligands, the receptors and CD4+ lymphocyte accounts.

Conclusions
===========

Plasma concentration of Fas receptors and Fas ligand, could be involved in the decrease in CD4+ cells in HIV-1 patients. Further studies on the role of the Fas complex in HIV pathogenesis in this population with significant viral diversity are needed. These studies would assess the potential role of FAS ligands and receptors as indicators of disease progression and or response to antiretroviral therapy.
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